Table 1.

Prognostic value of coagulation factor III/TF expression in breast cancer patients stratified according to different clinicopathological categories.

Classification	Status	Cases	HR 95% CI	p-Value
ALL	-	3951	0.78 (0.7–0.87)	8.4 × 10−5
Estrogen receptor (ER)	Positive (+)	2061	0.75 (0.64–0.89)	0.00069
	Negative (−)	801	1.17 (0.93–1.46)	0.18
Progesterone receptor (PR)	Positive	589	0.62 (0.43–0.88)	0.0074
	Negative	549	1.06 (0.79–1.41)	0.71
HER2	Positive	252	1.32 (0.85–2.04)	0.22
	Negative	800	0.81 (0.62–1.05)	0.11
ER, PR, HER2	Negative	255	1.27 (0.83–1.95)	0.27
Intrinsic subtype	Luminal A	1933	0.74 (0.62–0.87)	0.00044
	Luminal B	1149	0.81 (0.67–0.98)	0.031
	HER2	251	1.14 (0.78–1.68)	0.49
	Basal	618	1.13 (0.88–1.45)	0.35
ER, PR, HER2	Negative	186	1.63 (0.97–2.72)	0.06
Intrinsic subtype	Basal
ER, PR	Negative	115	0.89 (0.49–1.63)	0.72
HER2	Positive
Lymph node	Positive	1133	0.86 (0.7–1.04)	0.12
	Negative	2020	0.9 (0.76–1.06)	0.22
Grade	1	345	0.85 (0.51–1.44)	0.55
	2	901	0.94 (0.74–1.19)	0.59
	3	903	1.02 (0.82–1.27)	0.86
p53	Mutated	188	1.85 (1.13–3.01)	0.012
	Wild type	273	0.72 (0.47–1.1)	0.13
p53 mutated	ER+	65	0.83 (0.39–1.77)	0.63
	ER−	66	1.4 (0.65–3)	0.38
	PR+	25	1.52 (0.43–5.39)	0.51
	PR−	50	0.62 (0.25–1.53)	0.3
	HER2+	23	0.63 (0.18–2.23)	0.47
	HER2−	55	0.72 (0.29–1.76)	0.47
	Basal	74	2.56 (1.05–6.23)	0.032
p53 wild type	ER+	234	0.83 (0.53–1.3)	0.43
	ER−	29	0.71 (0.19–2.69)	0.61
	PR+	52	0.39 (0.12–1.27)	0.11
	PR−	24	4.4 (0.91–21.26)	0.044
	HER2−	60	1.04 (0.43–2.5)	0.93